EMA Withdrawn: Qoyvolma (ustekinumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

The EMA has withdrawn Qoyvolma (ustekinumab) from the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Psoriatic
• Crohn Disease
• Psoriasis
• Ulcerative Colitis

Drugs mentioned

• Qoyvolma (ustekinumab)

Snippet

Status: Withdrawn. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Colitis, Ulcerative;Crohn Disease. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 16/04/2026